Literature DB >> 28994424

Thyroid cancer: Cabozantinib effective in selected patients.

Peter Sidaway.   

Abstract

Entities:  

Year:  2017        PMID： 28994424     DOI： 10.1038/nrclinonc.2017.163

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.

Authors:  M Schlumberger; R Elisei; S Müller; P Schöffski; M Brose; M Shah; L Licitra; J Krajewska; M C Kreissl; B Niederle; E E W Cohen; L Wirth; H Ali; D O Clary; Y Yaron; M Mangeshkar; D Ball; B Nelkin; S Sherman
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976
  1 in total
  1 in total

1.  Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes.

Authors:  Fan Luo; Jiaxin Cao; Feiteng Lu; Kangmei Zeng; Wenjuan Ma; Yan Huang; Li Zhang; Hongyun Zhao
Journal:  Cancer Cell Int       Date:  2021-08-28       Impact factor: 5.722
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.